Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Otolaryngol. 2010 May-Jun;31(3):185-8. doi: 10.1016/j.amjoto.2009.02.001. Epub 2009 Apr 24.

Impact of preepiglottic space tumor involvement on concurrent chemoradiation therapy.

Author information

1
Division of Otolaryngology-Head and Neck Surgery, Duke University Medical Center, Durham, NC 27710, USA. walter.lee@duke.edu

Abstract

PURPOSE:

The aim of the study was to determine the prognostic impact of preepiglottic space (PES) involvement on local failure after concurrent chemoradiation therapy for squamous cell carcinoma.

MATERIALS AND METHODS:

Retrospective chart review of patients who underwent concurrent chemoradiation therapy for T3 or T4 laryngeal, T4 hypopharyngeal, and T3 or T4 oropharyngeal squamous cell carcinoma were eligible for inclusion. Patients were then stratified by the presence or absence of PES tumor involvement. A multivariate analysis was performed on the presence of recurrence using the following pretreatment variables: PES involvement, tumor extent, pathologic cell differentiation, lymph node involvement, age, and sex.

RESULTS:

A total of 102 patients were included in the study. Twenty-seven (28%) patients had documented PES involvement. Mean follow-up for all patients was 46 months. Involvement of the PES was not significantly associated with local tumor persistence or recurrence (P = .69). No other variables significantly impacted tumor recurrence.

CONCLUSION:

Preepiglottic space involvement does not negatively impact local tumor control after concurrent chemoradiation therapy.

PMID:
20015743
DOI:
10.1016/j.amjoto.2009.02.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center